[Use of bone marrow mesenchymal stem cells for ex vivo cartilage regeneration].
Articular cartilage disorders and injuries often result in lifelong chronic pain and compromised quality of life. When it comes to local articular cartilage defects, modern medicine is limited to short-term pain relief and inflammation control. In extreme cases the affected tissue is surgically removed and replaced by a synthetic prosthesis of limited durability. Cell-based therapies to regenerate articular cartilage have been in use since 1994. Such therapies provide a healthy population of cells to the injured site and require differentiated chondrocytes from the uninjured site as base material. Their usage often leads to donor site morbidity and they generate rigid fibrous cartilage where more flexible hyaline cartilage is required. The major restrictive factors for such methods are inadequate number and limited proliferation capacity of chondrocytes in vitro. Tissue engineering of adult marrow stromal cells/mesenchymal stem cells (MSCs) with their almost unlimited proliferation potential and proven capability to differentiate into chondrocytes for ex vivo generation of cartilage tissue still remains a vision. For optimal harnessing of MSCs as chondroprogenitor cells, basic background information regarding commitment to the lineage, cartilage differentiation and the regulatory factors and molecules involved is essential.
Grässel
S
S
Abteilung Experimentelle Orthopädie, Orthopädische Universitätsklinik Regensburg, Kaiser-Karl-V.-Allee 3, 93077, Bad Abbach. susanne.graessel@klinik.uni-regensburg.de
Ahmed
N
N
D016026:Bone Marrow Transplantation / Q000639:trends*; D002356:Cartilage / Q000473:pathology / Q000601:surgery*; D002357:Cartilage Diseases / Q000473:pathology / Q000601:surgery*; D050724:Fractures, Cartilage / Q000473:pathology / Q000601:surgery*; D006801:Humans; D045164:Mesenchymal Stem Cell Transplantation / Q000639:trends*; D010818:Practice Patterns, Physicians' / Q000639:trends; D023822:Tissue Engineering / Q000379:methods*